← The Wire
GILDNasdaq
GILEAD SCIENCES, INC.
Biological Products, (No Diagnostic Substances) · DE · CIK 882095
Gilead Sciences discovers, develops, and delivers innovative medicines to prevent and treat life-threatening diseases like HIV, viral hepatitis, COVID-19, and cancer
🔥 High media attention
$155.93B
Market cap
$126.33
Last close
-1.2%
1D
+1.2%
5D
6.9M
Volume
Price · last 39 sessions-4.8%
May 4L $121.48 · H $136.30Jun 29
172
Total filings
May 20, 2026
Last filing
12/31
Fiscal year end
424B5424B5May 18, 2026424B5424B5May 14, 2026424B5424B5Nov 15, 2024424B5424B5Nov 13, 2024424B5424B5Sep 11, 2023424B5424B5Sep 7, 2023424B5424B5Sep 25, 2020424B5424B5Sep 23, 2020
Insider Activity
In the 90 days to Mar 27, 2026: 4 sold $45.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 27, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 10,000 | $136.82 | $1.4M |
| Mar 16, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 3,000 | $144.23 | $433K |
| Mar 16, 2026 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $144.23 | $433K |
| Feb 27, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 6,419 | $145.18 | $932K |
| Feb 27, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 3,481 | $144.04 | $501K |
| Feb 27, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 100 | $145.71 | $15K |
| Feb 17, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 18,405 | $154.18 | $2.8M |
| Feb 17, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 9,395 | $154.91 | $1.5M |
| Feb 17, 2026 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $154.43 | $463K |
| Feb 17, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 200 | $155.62 | $31K |
| Feb 5, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 115,640 | $150.00 | $17.3M |
| Jan 28, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 5,032 | $139.54 | $702K |
| Jan 28, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 4,968 | $140.24 | $697K |
| Jan 23, 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 115,640 | $135.00 | $15.6M |
| Jan 20, 2026 | Bluestone JeffreyDirector | Sell | 5,000 | $123.50 | $618K |
| Jan 15, 2026 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $124.31 | $373K |
| Jan 15, 2026 | Mercier JohannaChief Commercial Officer | Sell | 3,000 | $124.31 | $373K |
| Dec 29, 2025 | O'Day Daniel PatrickChairman & CEO | Sell | 10,000 | $124.83 | $1.2M |
| Dec 15, 2025 | Mercier JohannaChief Commercial Officer | Sell | 3,000 | $122.00 | $366K |
| Dec 15, 2025 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $122.00 | $366K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 8 reputable articles · skews ▼ negative.
MarketWatchGilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains3d agoMarketWatchGilead Sciences Inc. stock outperforms competitors despite losses on the day11d agoMarketWatchGilead Sciences Inc. stock underperforms Wednesday when compared to competitors12d agoMarketWatchGilead Sciences Inc. stock outperforms competitors on strong trading day13d agoMarketWatchGilead Sciences Inc. stock underperforms Tuesday when compared to competitors20d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance